ClinicalTrials.gg

Program

N-Methyl-3,4-methylenedioxyamphetamine

Also written as “Midomafetamine HCl”, “Midomafetamine” and “midomafetamine HCl”.

Its studies are mostly in Stress Disorders, Post-Traumatic · Autism Spectrum Disorder · Autistic Disorder · Anxiety Disorders · Binge-Eating Disorder, led by 4 companies.

Furthest: phase 3, since May 14, 201829 company-led studies, 2 open or runningNext primary completion: Dec 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Resilient Pharmaceuticals262 open or runningphase 3since May 14, 2018Aug 24, 2004Dec 2028phase 1 · NCT03606538
Definium Therapeutics US10 open or runningphase 2since Dec 22, 2025Dec 22, 2025none ahead
MAPS Europe10 open or runningphase 2since Jul 19, 2019Jul 19, 2019none ahead
Remedy10 open or runningphase 2since Sep 19, 2021Sep 19, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 15 studies since Aug 24, 2004.

  1. May 14, 2018Phase 3 study in Stress Disorders, Post-TraumaticResilient Pharmaceuticals · NCT03537014 · 100 enrolled · United States, Canada, Israel
  2. Jul 20, 2018Phase 1 study in PharmacokineticsResilient Pharmaceuticals · NCT03606538 · 16 planned · United States
  3. Jul 19, 2019MAPS Europe’s first study: phase 2 study in Stress Disorders, Post-TraumaticNew to MAPS EuropeMAPS Europe · NCT04030169 · 21 enrolled · Czechia, Germany, Netherlands and more
  4. Jul 30, 2019Phase 1 study in Psychological Effects of Study DrugResilient Pharmaceuticals · NCT04073433
  5. Aug 30, 2019Phase 3 study in Stress Disorders, Post-TraumaticResilient Pharmaceuticals · NCT04077437 · 121 enrolled · United States, Israel
  6. Jun 26, 2020Phase 2 study in Binge-Eating DisorderResilient Pharmaceuticals · NCT04454684
  7. Jan 14, 2021Phase 3 study in Stress Disorders, Post-TraumaticResilient Pharmaceuticals · NCT04714359 · 87 enrolled · United States, Canada, Israel
  8. Mar 2, 2021Phase 2 study in Stress Disorders, Post-TraumaticResilient Pharmaceuticals · NCT04784143 · 26 enrolled · United States
  9. Jul 9, 2021Phase 2 study in Stress Disorders, Post-TraumaticResilient Pharmaceuticals · NCT04968938
  10. Sep 19, 2021Remedy’s first study: phase 2 study in Stress Disorders, Post-TraumaticNew to RemedyRemedy · NCT05067244 · 10 enrolled · Canada
  11. Nov 24, 2021Phase 1 study in PharmacokineticsResilient Pharmaceuticals · NCT05147402 · 14 enrolled · United States
  12. Dec 13, 2021Phase 2 study in Stress Disorders, Post-TraumaticResilient Pharmaceuticals · NCT05173831
  13. Dec 22, 2025Definium Therapeutics US’s first study: phase 2 study in Autism Spectrum DisorderNew to Definium Therapeutics USDefinium Therapeutics US · NCT07303907 · 5 enrolled · United States
  14. Apr 30, 2026Phase 1 study in Healthy VolunteersResilient Pharmaceuticals · NCT07584720 · 32 enrolled · United States

Ahead

  1. Dec 2028Primary completion: phase 1 study in PharmacokineticsResilient Pharmaceuticals · NCT03606538

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 29 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07584720Healthy Volunteers · United States1Active, not recruitingResilient PharmaceuticalsJul 23, 202632
NCT07303907Autism Spectrum Disorder · United States2CompletedDefinium Therapeutics USSep 16, 20265
NCT05173831Stress Disorders, Post-Traumatic2WithdrawnResilient PharmaceuticalsDec 20240
NCT05147402Pharmacokinetics · United States1CompletedResilient PharmaceuticalsDec 2, 202214
NCT05067244Stress Disorders, Post-Traumatic · Canada2CompletedRemedyNov 1, 202410
NCT04968938Stress Disorders, Post-Traumatic2WithdrawnResilient PharmaceuticalsAug 20230
NCT04784143Stress Disorders, Post-Traumatic · United States2TerminatedResilient PharmaceuticalsJun 25, 202426
NCT04714359Stress Disorders, Post-Traumatic · United States, Canada, Israel3CompletedResilient PharmaceuticalsNov 1, 202387
NCT04454684Binge-Eating Disorder2WithdrawnResilient PharmaceuticalsAug 10, 20280
NCT04077437Stress Disorders, Post-Traumatic · United States, Israel3CompletedResilient PharmaceuticalsOct 30, 2022121
NCT04073433Psychological Effects of Study Drug1WithdrawnResilient PharmaceuticalsDec 20250
NCT04030169Stress Disorders, Post-Traumatic · Czechia, Germany, Netherlands and more2CompletedMAPS EuropeDec 14, 202321
NCT03606538Pharmacokinetics · United States1Not yet recruitingResilient PharmaceuticalsDec 202816
NCT03537014Stress Disorders, Post-Traumatic · United States, Canada, Israel3CompletedResilient PharmaceuticalsAug 11, 2020100
NCT03485287Stress Disorders, Post-Traumatic · Canada2CompletedResilient PharmaceuticalsJun 4, 20194
NCT03282123Stress Disorders, Post-Traumatic · United States2CompletedResilient PharmaceuticalsAug 10, 201938
NCT03181763Startle Response · United States1CompletedResilient PharmaceuticalsAug 1, 202034
NCT02876172Stress Disorders, Post-Traumatic · United States2CompletedResilient PharmaceuticalsDec 16, 201712
NCT02427568Anxiety Disorders · United States2CompletedResilient PharmaceuticalsApr 25, 201718
NCT02008396Autistic Disorder · United States2CompletedResilient PharmaceuticalsApr 28, 201712
NCT01958593Stress Disorders, Post-Traumatic · Canada2TerminatedResilient PharmaceuticalsSep 10, 20156
NCT01793610Stress Disorders, Post-Traumatic · United States2CompletedResilient PharmaceuticalsDec 3, 201529
NCT01689740Stress Disorders, Post-Traumatic · Israel2CompletedResilient PharmaceuticalsApr 7, 201610
NCT01458327Stress Disorders, Post-Traumatic · United States2CompletedResilient PharmaceuticalsJun 27, 20143
NCT01404754Psychological Effects of Study Drug · United States1CompletedResilient PharmaceuticalsAug 5, 2022107
NCT01211405Stress Disorders, Post-Traumatic · United States2CompletedResilient PharmaceuticalsJun 4, 201526
NCT00402298Stress Disorders, Post-Traumatic · Israel2TerminatedResilient PharmaceuticalsMar 20095
NCT00353938Stress Disorders, Post-Traumatic · Switzerland2CompletedResilient PharmaceuticalsSep 2, 200914
NCT00090064Stress Disorders, Post-Traumatic · United States2CompletedResilient PharmaceuticalsMay 2, 200823

How it is read

Names in the registry

  • “Midomafetamine HCl”, 10 entries
  • “Midomafetamine”, 7 entries
  • “midomafetamine HCl”, 2 entries
  • “MDMA”, 2 entries
  • “midomafetamine”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.